Real world study of Innovator Infliximab (REMICADE) and Biosimilar Infliximab in a Treatment Naive Turkish Rheumatologic Disease Population

Trial Profile

Real world study of Innovator Infliximab (REMICADE) and Biosimilar Infliximab in a Treatment Naive Turkish Rheumatologic Disease Population

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatic disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 28 Nov 2016 New trial record
    • 14 Nov 2016 Real-World data published in a Janssen Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top